An official website of the United States government

Therapy for transthyretin-associated amyloidosis

Patent
US-9610270-B2
Inventor

CENTELLAS CASADO MARC (ES)

INSA BORONAT RAÚL (ES)

REIG BOLAÑO NURIA (ES)

GAVALDÀ BATALLA NÚRIA (ES)

Assignee
SOM INNOVATION BIOTECH S L (ES)
Country
United States
Dates
  • Priority:
    2011/10/24
  • Grant:
    2017/04/04
Description
This web page summarizes information in PubChem about patent US-9610270-B2. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page.

1 Abstract

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

2 Full Text

3 Important Dates

3.1 Priority Date

2011/10/24

3.2 Filing Date

2012/10/23

3.3 Publication Date

2017/04/04

3.4 Grant Date

2017/04/04

4 Inventor

CENTELLAS CASADO MARC (ES)

INSA BORONAT RAÚL (ES)

REIG BOLAÑO NURIA (ES)

GAVALDÀ BATALLA NÚRIA (ES)

5 Assignee

SOM INNOVATION BIOTECH S L (ES)

6 Country

United States

7 Linked Chemicals

7.1 PubChem Compounds

7.2 PubChem Substances

8 Patent Family

9 Classification

9.1 IPC

A61K31/353 (inventive)

A61K31/42 (inventive, first)

A61K31/192 (inventive)

A61K31/165 (inventive)

A61K31/198 (inventive)

A61K31/12 (inventive)

A61K31/423 (inventive)

A61K45/06 (inventive)

A61K31/603 (inventive)

9.2 CPC

A61P43/00 (inventive)

A61P25/28 (inventive)

A61P25/00 (inventive)

A61K45/06 (inventive)

A61K31/353 (inventive)

A61K31/423 (inventive)

A61K31/192 (inventive)

A61K31/603 (inventive)

A61K31/198 (inventive, first)

A61K9/20

A61K31/12 (inventive)

A61K31/138

A61K2300/00

10 Citations

  • WO-9512815-A1 (APP)
  • WO-9827972-A2 (APP)
  • WO-0222551-A1 (APP)
  • WO-03013442-A2 (APP)
  • WO-03063880-A1 (APP)
  • WO-2005079795-A2 (APP)
  • WO-2005094218-A2 (APP)
  • WO-2005113523-A1 (APP)
  • WO-2005112913-A1 (APP)
  • US-2005282780-A1 (APP)
  • WO-2006026555-A2 (APP)
  • GB-2429645-A (APP)
  • CN-1953746-A (APP)
  • WO-2008013764-A2 (APP)
  • CN-101198598-A (APP)
  • RU-2394570-C2 (APP)
  • US-2010249233-A1 (APP)
  • WO-2011110396-A1 (APP)
  • RU-2428987-C2 (APP)
  • Benson, "Amyloidosis," in Scriver et al. "The Metabolic and Molecular Basis of Inherited Disease," McGraw-Hill Medical, 8th Edition, pp. 5345-5378 (2001). (APP)
  • Di Giovanni et al. "Entacapone and Tolcapone, Two Catechol-O-Methyltransferase Inhibitors, Block Fibril Formation of Alpha-Synuclein and Beta-Amyloid and Protect Against Amyloid-Induced Toxicity," J. Biol. Chem., vol. 285, pp. 14941-14954 (2010). (APP)
  • Dolado et al. "Kinetic Assay for High-Throughput Screening of In Vitro Transthyretin Amyloid Fibrillogenesis Inhibitors", J. Comb. Chem., vol. 7, pp. 246-252 (2005). (APP)
  • Ferreira et al. "Natural Polyphenols Inhibit Different Steps of the Process of Transthyretin (TTR) Amyloid Fibril Formation," FEBS Lett., vol. 585, pp. 2424-2430 (2011). (APP)
  • Ferreira et al. FEBS Lett., vol. 583, pp. 3569-3576 (2009). (APP,APP)
  • Gales et al. "Human Transthyretin in Complex with Iododiflunisal: Structural Features Associated with a Potent Amyloid Inhibitor", Blochem J., vol. 388, pp. 615-621 (2005). (APP)
  • Gupta et al., "Design of Mechanism-Based Inhibitors of Transthyretin Amyloidosis: Studies with Biphenyl Ethers and New Structural Templates," J, Med. Chem., 50, pp. 5589-5599 (2007). (APP)
  • Hurshman et al. "Transthyretin Aggregation under Partially Denaturing Conditions is a Downhill Polymerization," Biochemistry, vol. 43, pp. 7365-7381 (2004). (APP)
  • Idicula-Thomas et al. "Protein Aggregation: A Perspective from Amyloid and Inclusion-body Formation," Current Science, vol. 92, pp. 758-767 (2007). (APP)
  • International Perliminary Report on Patentability and Written Opinion of the International Searching Authorirty corresponding to International Application No. PCT/EP2012/070945 dated Apr. 29, 2014. (APP,APP)
  • International Search Report corresponding to PCT/EP2012/070945 dated Feb. 18, 2013. (APP,APP)
  • Klabunde et al. "Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors", Nature Structural Biology, vol. 7, pp. 312-321 (2000). (APP)
  • Lee et al. "Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomer," Nature Chemical Biology, vol. 7, pp. 602-609 (2011). (APP)
  • Männistö et al. "Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors", Pharmacol. Rev., vol. 51, pp. 593-628 (1999). (APP)
  • Mannisto et al. "Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors", vol. 51, pp. 593-628 (1999). (APP)
  • Nippon Rinsho (Japanese journal of clinical medicine), vol. 49, No. 4, pp. 10-17 (Apr. 1991). (APP,APP)
  • Translation of Office Action corresponding to Russian Patent Application No. 2014114930 dated Sep. 5, 2016. (APP,APP)
  • Wood et al. "α-Synuclein Fibrillogenesis is Nucleation-dependent: Implications for the Pathogenesis of Parkinson's Disease," J. Biol. Chem., vol. 274, No. 28, pp. 19509-19512 (1999). (APP)

11 Cited By

12 Similar Patents

13 Information Sources

  1. Google Patents
    LICENSE
    "Google Patents Research Data" by Google, based on data provided by IFI CLAIMS Patent Services and OntoChem, is licensed under a Creative Commons Attribution 4.0 International License.
    https://creativecommons.org/licenses/by/4.0/legalcode
  2. PubChem
CONTENTS